Our goal is to vastly improve patient care and outcomes by bringing innovative eyecare technology to the healthcare industry. We want to significantly advance the efficacy and safety of existing eyecare drugs, while developing new ophthalmic drugs that address many unmet medical needs.
Through our unique and extensive partnerships, we are able to identify and launch new technologies into beneficial treatments that can help many patients worldwide.
DENKI® is a registered trademark of Pharmaleads SA.
We are currently exploring partnerships and development opportunities that would support the development and commercialization of our pipeline products.
We have acquired rights to multiple products since our inception in 2016.
We plan to initiate clinical trials for both IC265 and IC270 in 2021. Both IC800 and IC805 are being developed and prepared for an IND.
on the horizon
Damon is an experienced Pharmaceutical Executive with 20 years experience working in the life sciences and healthcare industries. He has experience in large and small pharmaceutical companies and has successfully navigated numerous drug development programs through the FDA regulatory approval process and commercial launch. He has extensive Public Policy experience and has worked with numerous Federal and State Agencies on the Regulatory challenges of commercialization.
Steve has 30+ years of demonstrated success in the pharmaceutical/biotech and medical device industries. He has held various executive leadership and management positions within R&D and has lead numerous global Rx, OTC, and device projects.
Prior to joining IACTA, Steve provided his expertise to pharmaceutical and device companies as a Management Consultant. He used is cumulated knowledge of portfolio management, project management, strategic planning, clinical operations, IT, QC/QA, biostatistics, and data management to help develop a number of new technologies.
Steve has also held various executive positions at Allergan Inc. for over 18 years. He served as a member of the R&D executive governance committees whose responsibilities included the successful development and global registration of key products, as well as the oversight of projects, budgets, facilities, human capital, and R&D productivity.
Steve has a Masters in Business Administration from the University of Missouri and an Honors Degree in Biochemistry and Pharmacology from the University of Western Ontario.
Orest has more than 35 years of product development experience, covering both small and large molecules, including novel ocular drug delivery systems, within the pharmaceutical industry. Prior to joining IACTA, Orest was the Senior Vice President of Global Pharmaceutical Sciences at Allergan, Inc. He also held positions at Johnson & Johnson, CooperVision, and Fisons.
Orest has contributed to well over 30 regulatory submissions, representing a successfully strong track record for product approvals worldwide, with a predominant emphasis in ophthalmology. He was also a pivotal contributor and inventor covering numerous marketed products including those used in the treatment of glaucoma and dry eye.
Orest is a fellow of the Royal Pharmaceutical Society of Great Britain. He received his Ph.D. from the University of Nottingham, UK and his B.Sc. (Hons) in Pharmacy from the Sunderland School of Pharmacy, UK.
He has held academic positions, most recently as visiting professor at the Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Scotland.
Will is Chief Administrative Officer for IACTA. He is a biotech entrepreneur who has co-founded several biotech companies; one of which was sold for $70 million. Will was most recently the President, Operations for Scilex Pharmaceuticals, a company which he co-founded and recently received approval for and launched a prescription non-opioid drug for the treatment of pain. Will's past experience includes working as a partner at national law firms as well as the Vice President, General Counsel and member of the Executive Committee of a publicly traded, commercial-stage biotech company that operated globally. Will has experience with oversight of all operations of a company, including commercial, R&D, finance, manufacturing, corporate governance, legal, compliance, regulatory, business development, international operations, litigation/disputes, securities and intellectual property functions.
Will earned a Juris Doctor (JD) degree in law from Georgetown University Law Center and a Bachelor of Sciences (BS) in Business Entrepreneurship from the University of Southern California.
George, Chief Business Officer for IACTA, overseeing business development, corporate development and capital raising, is a seasoned life sciences industry executive. He has founded and/or led multiple companies, including Scilex Pharmaceuticals, Inc., where he was Co-Founder and President, Business, and led the company through development, clinical trials, NDA submission, FDA approval, $140 million financing and commercial launch of the company’s first FDA-approved drug product. George has also held various other senior management positions, including Board Director, Managing Director, Chief Administrative Officer, Corporate Secretary, Chief Legal Officer, General Counsel, Chief Compliance Officer and Chief Intellectual Property Counsel, with publicly-traded and private, global biotechnology and pharmaceutical companies, including Sorrento Therapeutics, Inc. (NASDAQ: SRNE), BioDelivery Sciences International, Inc. (NASDAQ: BDSI), Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) and Alpharma, Inc. (now, a part of Pfizer Inc.). In these roles, George helped lead the development and commercialization efforts and launches of multiple pharmaceutical drug products. Previously, in private practice, George was a partner in two AMLAW 200 law firms, where he had leadership roles, including establishing the life sciences practice group for one firm and heading it as the national co-chair. Additionally, George is a current member of the Board of Directors for multiple companies, including Morphogenesis, Inc. and Calidi Biotherapeutics, Inc.
George earned a Juris Doctor (JD) degree in law from the University of Notre Dame School of Law and a Bachelor of Arts and Sciences (BAS) dual degree in Biochemistry & Economics from the University of California, Davis.